April 16, 2019
WELLESLEY, Mass., April 16, 2019–Increasing research and development activities, significant investments by pharmaceutical and biotech companies, and the increasing adoption of cell line technologies in cell-based assays are factors expected to contribute to growth in the cell line and membrane market, according to a BCC Research, “Cell Line and Membrane Market.”
The industry expects to see a compound annual growth rate (CAGR) of 5.1% through 2023, when it could be worth $220.3 million.
“Increasing investment in R&D in cell culture technology, high investments by pharmaceutical and biotechnology companies for drug development, and increasing adoption of cell line technologies in cell-based assays are some major factors that are expected to promote the growth of the global cell line and membrane market,” notes report author Sathya Durga.
United States Leads Market by Size and Growth
The United States currently leads the market by both growth and size, with a 2018 value of $102.3 million and a CAGR through 2023 of 5.7%. Growth is due to government efforts to promote CRISPR technology and investments which support drug development activities.
Editors/reporters requesting analyst interviews should contact Sarah Greenberg at firstname.lastname@example.org.
Cell Line and Membrane Market( BIO178A )
Publish Date: Mar 2019
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email email@example.com or visit www.bccresearch.com/media to request access to our library of market research.